Q1 Earnings Forecast for biote Issued By B. Riley

biote Corp. (NASDAQ:BTMD) – B. Riley issued their Q1 2025 earnings per share estimates for biote in a research note issued on Thursday, March 13th. B. Riley analyst J. Van. Sinderen expects that the company will post earnings per share of $0.04 for the quarter. The consensus estimate for biote’s current full-year earnings is $0.75 per share. B. Riley also issued estimates for biote’s Q2 2025 earnings at $0.05 EPS, FY2025 earnings at $0.29 EPS, FY2026 earnings at $0.42 EPS and FY2027 earnings at $0.71 EPS.

Separately, Craig Hallum decreased their target price on biote from $12.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, March 13th.

biote Stock Performance

NASDAQ:BTMD opened at $4.00 on Monday. The company has a market capitalization of $217.35 million, a price-to-earnings ratio of 15.38 and a beta of 1.07. biote has a one year low of $3.04 and a one year high of $8.44. The stock has a 50-day simple moving average of $4.92 and a 200 day simple moving average of $5.53.

Hedge Funds Weigh In On biote

A number of hedge funds and other institutional investors have recently bought and sold shares of BTMD. Victory Capital Management Inc. acquired a new position in shares of biote during the third quarter worth approximately $106,000. MetLife Investment Management LLC boosted its position in shares of biote by 129.1% during the third quarter. MetLife Investment Management LLC now owns 16,582 shares of the company’s stock worth $93,000 after buying an additional 9,343 shares during the period. Wasatch Advisors LP boosted its position in shares of biote by 8.4% during the third quarter. Wasatch Advisors LP now owns 1,392,809 shares of the company’s stock worth $7,772,000 after buying an additional 107,792 shares during the period. Jacobs Levy Equity Management Inc. boosted its position in shares of biote by 24.9% during the third quarter. Jacobs Levy Equity Management Inc. now owns 272,377 shares of the company’s stock worth $1,520,000 after buying an additional 54,302 shares during the period. Finally, Quarry LP acquired a new position in shares of biote during the third quarter worth approximately $104,000. 21.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at biote

In related news, major shareholder Guines Llc bought 750,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The stock was bought at an average cost of $3.22 per share, for a total transaction of $2,415,000.00. Following the completion of the purchase, the insider now directly owns 3,820,938 shares in the company, valued at approximately $12,303,420.36. The trade was a 24.42 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 13.90% of the stock is currently owned by insiders.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.